Simcere Pharma - About the company
Simcere Pharma is a public company based in Nanjing (China), founded in 1995 by Jinsheng Ren. It operates as a Developer of innovative oncology and immunology therapeutics. The company has 1239 active competitors, including 43 funded and 337 that have exited. Its top competitors include companies like Bayer, Teva Pharmaceuticals and Wockhardt.
Company Details
Developer of innovative oncology and immunology therapeutics. This company focuses on the research, development, and commercialization of novel treatments for cancer and autoimmune diseases. Its pipeline includes antibody-drug conjugates (ADCs) and other biologics targeting specific disease pathways. The company has a robust manufacturing and distribution network supporting its product portfolio. It also engages in collaborative research and development partnerships to accelerate the delivery of new therapies to patients.
- Website
- www.simcere.com/
- Registered Address
- KING COURT BUSINESS CENTRE,LONDON ROAD,STEVENAGE,UNITED KINGDOM,SG1 2NG
Key Metrics
Founded Year
1995
Location
Nanjing, China
Stage
Public
Investors
Ranked
28th among 1239 active competitors
Employee Count
1,137 as on Sep 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Simcere Pharma
Simcere Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
SIMCERE UK LIMITED CIN: 11120475 , United Kingdom, Active | Dec 19, 2017 | - | 3 (As on Dec 31, 2024) |
Simcere Pharma's IPO details
Simcere Pharma got listed on Apr 20, 2007.
Click here to take a look at Simcere Pharma's IPO in detail
Sign up to download Simcere Pharma's company profile
Simcere Pharma's funding and investors
Simcere Pharma is a funded company. Simcere Pharma has 4 institutional investors.
View details of Simcere Pharma's funding rounds and investors
Simcere Pharma's founders and board of directors
Founder? Claim ProfileThe founders of Simcere Pharma is Jinsheng Ren.
Here are the details of Simcere Pharma's key team members:
- Jinsheng Ren: Co-Founder & Chairman of Simcere Pharma.
- Hongquan Liu: CEO of Simcere Pharma.
View details of Simcere Pharma's Founder profiles and Board Members
Simcere Pharma's employee count trend
Simcere Pharma has 1,137 employees as of Sep 26. Here is Simcere Pharma's employee count trend over the years:
Uncover Simcere Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Simcere Pharma's Competitors and alternates
Top competitors of Simcere Pharma include Bayer, Teva Pharmaceuticals and Wockhardt. Here is the list of Top 10 competitors of Simcere Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Manufacturer of drugs | - | 76/100 | ||
2nd |  Teva Pharmaceuticals 1901, Petah Tikva (Israel), Public | Traditional company engaged in manufacturing generics | $500M | 75/100 | |
3rd | Manufacturer of pharmaceuticals, biotechnology products, and active pharmaceutical ingredients | - | 71/100 | ||
4th |  Biological E 1953, Hyderabad (India), Funding Raised | Developer of vaccines for treating multiple diseases | - | 69/100 | |
5th | Manufacturer of APIs, generic drugs, and formulation development services | - | 69/100 | ||
6th | The Alvogen 2009, Morristown (United States), Acquired | Developer and marketer of pharmaceutical products | $156M | 69/100 | |
7th | Developer, manufacturer, and markets a broad range of pharmaceutical products | $50M | 68/100 | ||
8th | Amneal 2002, Bridgewater (United States), Public | Manufacturer of generics formulations | - | 68/100 | |
9th | Laboratorio Reig Jofre 2000, Barcelona (Spain), Public | Manufacturer of pharmaceutical products and food supplements | - | 68/100 | |
10th | Strides Pharma Science 1990, Bengaluru (India), Public | Manufacturer of generic pharmaceutical products and various specialty medical formulations | - | 68/100 | |
28th | Simcere Pharma 1995, Nanjing (China), Public | Developer of innovative oncology and immunology therapeutics | - | 63/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Simcere Pharma's competitors? Click here to see the top ones
Simcere Pharma's Investments and acquisitions
Simcere Pharma has made 3 investments including Carmine Therapeutics, NeuroDawn and Veritas Genetics. Simcere Pharma has not made any acquisitions as of now.Here is the list of its investments:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Oct 13, 2022 | Investments | 2019 | Singapore (Singapore) | |
Aug 23, 2021 | Investments | 2021 | ||
Oct 17, 2016 | Investments | 2014 | Danvers (United States) |
_1573529694590.png?devicePixelRatio=2&height=20&width=20){kind=logo}
_1584017279218.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Want to know more about where corporates are investing? Sign up today!See all investments by Simcere Pharma
News related to Simcere Pharma
Filter this listMedia has covered Simcere Pharma for a total of 19 events in the last 1 year, 6 of them have been about company updates and 4 about partnerships.
•
Lynk Pharmaceuticals and Simcere Expand Collaboration for Zemprocitinib in Dermatology in APACPR Newswire•Nov 02, 2026•Simcere Pharma, lynkpharma.com
•
Simcere Zaiming, Roche Ink License Agreement for Antibody Targeting B-Cell-Mediated DiseasesContract Pharma•Sep 01, 2026•Simcere Pharma, Roche
•
Simcere Launches RMB1 Billion Share Buyback to Signal Confidence in OutlookTipRanks•Aug 20, 2026•Simcere Pharma
•
Leadman Acquires Simcere Sanroad for 1.39 Billion YuanG-MedTech•Jun 16, 2026•Beijing Leadman Biochemistry, Simcere Pharma
•
Simcere Pharmaceutical Partners with Stanford Medicine for Innovative IPF TherapiesPR Newswire•Jun 12, 2026•Stanford, Simcere Pharma
•
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026GlobeNewswire•Apr 21, 2026•NextCure, Simcere Pharma
•
Simcere Acquires Shanghai Jina Enterprise Assets for CNY 5.28 BillionMar 18, 2026•Simcere Pharma
•
Boehringer Ingelheim and Simcere partner to advance antibody treatment for IBDGlobeNewswire•Jan 27, 2026•Simcere Pharma, Boehringer Ingelheim
•
Simcere to Expand Global Presence and Focus on Neuroscience, OncologyChina Daily•Jan 06, 2026•Simcere Pharma
•
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugateFinancial Post•Dec 22, 2025•Simcere Pharma, Ipsen
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Simcere Pharma
Explore our recently published companies
- Lee’s PHARM - Hong Kong based, 2002 founded, Public company
- HBS Healthcare - Preston based, 2009 founded, Unfunded company
- MEDPLUS WORLDWIDE - Kowloon based, 2013 founded, Deadpooled company
- Zentarido Pharma Company - Plymouth based, 2018 founded, Deadpooled company
- Mooni Studio - Seoul based, 2018 founded, Funding Raised company
- Mandevis Pharma - Nangal based, 2015 founded, Deadpooled company
